Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will ...

Details for Auron’s poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B Protein ...

Details for Auron’s poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B ...

Details for Auron's poster presentation are below and can be found via the AACR online itinerary planner: Abstract Number and Title: Abstract #350: AUTX-703, a Novel and Potent KAT2A and KAT2B Protein ...

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last four decades, there have ...